Pfizer Says TALZENNA-XTANDI Kept 77% Progression-Free at 3 Years in Advanced Prostate Cancer
Updated
Updated · StockTitan · May 30
Pfizer Says TALZENNA-XTANDI Kept 77% Progression-Free at 3 Years in Advanced Prostate Cancer
3 articles · Updated · StockTitan · May 30
Phase 3 TALAPRO-3 data showed men with HRR gene-mutated metastatic castration-sensitive prostate cancer had an estimated 77% chance of remaining progression-free at three years on TALZENNA plus XTANDI.
The combination cut the risk of radiographic progression or death by more than 50% versus standard care, with benefit seen across prespecified groups including BRCA and non-BRCA alterations.
599 patients were enrolled in the randomized, double-blind study, whose detailed results were presented at ASCO 2026 and published in The New England Journal of Medicine.
Interim overall survival showed a favorable trend, with a hazard ratio of 0.77 and median survival not yet reached in either arm.
Pfizer said no new safety signals emerged; anemia was the most common severe adverse event, and the company is discussing a label expansion with global regulators.
With next-gen drugs in trials, could this toxic combination become obsolete before its ultimate survival benefit is even proven?
Given severe anemia in half of patients, is delaying cancer progression worth the significant impact on daily quality of life?
As this combo works on more gene mutations, will complex genetic testing for prostate cancer soon become a thing of the past?